Answers are grounded in this paper and cite their sources.
Osteoblasts and marrow stromal cells are known to mediate the bone resorptive effects of osteotropic hormones and cytokines. The mechanism by which osteoblasts and stromal cells regulate osteoclastogenesis and osteoclast activation has been elusive. Recent discoveries have elucidated a signaling pathway that satisfies the requirements for this mediation. Osteoprotegerin ligand (OPGL), RANK, and osteoprotegerin (OPG) form a signal (agonist), receptor, and decoy receptor (antagonist) triad. OPG was discovered first as an inhibitor of osteoclastogenesisin vivo and in vitro.OPGL was identified by its binding affinity to OPG and is a potent stimulator of osteoclast differentiation, activation, and survival, in the absence of stromal cells. OPGL was found to be identical to TRANCE, which has been identified as a ligand for a tumor necrosis factor (TNF) receptor family member named RANK. RANK has been confirmed as the appropriate receptor for the effects of OPGL on bone resorption. Gene deletion studies in mice have shown that OPG is essential to maintain normal bone mass in mice and OPGL is essential for osteoclast formation. Osteotropic hormones and cytokines regulate OPG and OPGL expression in osteoblasts and marrow stromal cells to increase the OPGL signal for bone resorption. The Endocrinologist 2000; 10: 18-26 Learning Objectives: Review in vitro and animal studies that have clarified the role of osteoprotegerin (OPG), OPG ligand (OPGL), and OPGL receptor in regulating bone metabolism. In what ways does OPG interact with exogenous hormones and cytokines, and how does it help to regulate bone calcium metabolism? Be aware of potential clinical treatments for pathologic bone resorption aimed at the OPG/OPGL/OPGL receptor pathway.
No takes yet. Share an insight, caveat, or question.
Colin Robert Dunstan (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: